Trial of new imaging agent nears completion

Early this morning, Progenics Pharmaceuticals announced completion of enrollment of patients in the Phase II/III OSPREY trial of a new PSMA-targeted PET/CT imaging agent for detection of prostate cancer. … READ MORE …

More new drugs; more new trials

Two small companies have today announced initial clinical trials of two new investigational agents for the treatment of prostate cancer. … READ MORE …